Medtronic (MDT) Earnings Date & Reports

Key Takeaways

• Revenue reached $9.76 billion, up 13.7% year over year on both a reported and organic basis, topping consensus estimates near $9.55 billion.
• Adjusted earnings per share (EPS, profit divided by shares outstanding) came in at $1.45, up 15.1% and $0.06 above the $1.39 consensus.
• On a GAAP basis (Generally Accepted Accounting Principles, the standard U.S. accounting method), EPS was $1.14, up from $0.81 a year earlier.
• Medtronic raised its full-year outlook: organic revenue growth of 7.25%–7.75% and adjusted EPS of $5.94–$6.00.
• Growth was boosted by an extra selling week in the 53-week fiscal year, which added roughly $570 million to organic growth.

Earnings Context and Why It Matters

Medtronic is one of the world's largest medical-device makers, and its quarterly results serve as a broad barometer for elective procedure volumes and hospital capital spending. The first quarter of fiscal 2027, which ended July 31, 2026, offered investors a first look at whether the company's newer growth platforms could sustain momentum beyond its core cardiac franchises. The report also matters because it marked the first full quarter under the company's revised segment structure and included the early contribution of recent acquisitions. With the company planning to separate its Diabetes business by fiscal year-end, the quarter's broad-based strength gave management confidence to lift its full-year guidance.

Reported Results

Medtronic reported first quarter fiscal 2027 revenue of $9.756 billion, an increase of 13.7% compared with $8.578 billion in the prior-year period. Organic revenue also grew 13.7%. Adjusted EPS rose 15.1% to $1.45, ahead of the $1.39 consensus and $0.06 above the midpoint of the company's own guidance. GAAP EPS was $1.14, up from $0.81 a year earlier.

Growth was notably broad-based across the portfolio. Cardiovascular revenue rose 19.5% to $3.927 billion, led by Electrophysiology Therapies, up 29.1% organically. Within that segment, Cardiac Ablation Solutions (CAS, treatments that address irregular heart rhythms) surged 88% worldwide. Neuroscience grew 10.3% to $2.678 billion, Medical Surgical rose 10% to $2.279 billion, and Diabetes increased 16.9% to $843 million.

Profitability was modestly firmer, with adjusted gross margin of 65.2% and adjusted operating margin of 23.7%, each up about 10 basis points (0.10 percentage point) year over year. Management also lifted full-year guidance, citing execution across the portfolio.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors following medical-device names like Medtronic, it offers a structured way to identify comparable opportunities. Explore the AI Screener to refine your own watchlist.

Market Reaction and Investor Sentiment

Shares of Medtronic climbed in pre-market trading after the results were released, reflecting an initial positive response to the revenue and EPS beat plus the raised guidance. Still, some observers noted a more measured move during the session, as the magnitude of the beat was partly attributed to an extra selling week rather than purely organic demand. That nuance tempered enthusiasm, with investors weighing the durability of the quarter's strong growth against the one-time calendar benefit. Sentiment around the stock remains broadly constructive, supported by strength in electrophysiology and the company's newer growth platforms, even as margin expansion stayed relatively modest.

Forward Outlook and Key Factors to Monitor

Following the raised guidance, investors will be watching whether Medtronic can maintain momentum once the extra-week benefit rolls off. Management's second-quarter outlook implies organic revenue growth of roughly 6%, a step down from the first quarter's 13.7%, underscoring how much of the beat was calendar-driven.

A central area to monitor is Cardiac Ablation Solutions and the Affera/Sphere-9 platform, where rapid installed-base growth and share gains are expected to continue, albeit against increasingly difficult comparisons later in the fiscal year. Renal denervation, pelvic health, and the Hugo robotic-surgery system represent earlier-stage growth drivers that will need to show sustained adoption.

On the financial side, watch for margin trajectory, since faster-growing but lower-margin businesses such as Diabetes and CAS could pressure profitability. Foreign exchange is expected to be a modest headwind for the full year. Finally, the planned separation of the Diabetes unit ahead of fiscal year-end remains a key structural catalyst, and any update on its timing or structure could influence investor sentiment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations